Fig. 4: Validation of RGC-iNs by RNA-seq. | npj Regenerative Medicine

Fig. 4: Validation of RGC-iNs by RNA-seq.

From: Human retinal ganglion cell neurons generated by synchronous BMP inhibition and transcription factor mediated reprogramming

Fig. 4

a Principal Component Analysis (PCA) plot of day 6 CTL, NAIP2 and PSC (top) and NEUROG2, NA, NAIP2-nc and NAIP2 cells (bottom). b Venn diagram of the number of genes expressed in each sample (normalized count >10). c Heatmap of the top 500 genes expressed in the NAIP2 samples. d Bar graph depicting −log10(FDR) of significantly differentially expressed pathways between NAIP2 and CTL samples identified by DAVID in Uniprot (top) and KEGG Gene Ontology (bottom) databases. e Scatterplots showing normalized counts of pan-neuronal and RGC marker genes in each treatment group. f Heatmaps of genes expressed within the neurogenesis (left), axon guidance (center), and growth factor (right) pathways. g Volcano plot highlighting log2(FC) gene expression between the CTL and NAIP2 samples plotted with respect to −log10(FDR). Immunostaining for VIM and GLAST in control cells (left) and PAX6, ISL1, POU4F1, and MAP2 in NAIP2 samples (right). FDR = false discovery rate. FC = fold change. Scale g = 85 µm. NAIP2-nc = RGC-iNs from non-clonally selected PSCs.

Back to article page